Funding for this research was provided by:
Guarantors of Brain
Migraine Trust
Migraine Trust
King's College London
Article History
Received: 18 October 2020
Revised: 21 November 2020
Accepted: 4 December 2020
First Online: 5 January 2021
Compliance with ethical standards
:
: The authors report no relevant conflicts of interest related to this work. Separate to this work, NK has received honoraria from Novartis Pharmaceuticals and Teva Pharmaceuticals, and writer honoraria from Continuum and Medicine (MPMED). PB has received honoraria from Teva Pharmaceuticals and writer honoraria from Continuum. JN has no disclosures to report. PJG reports, over the last 36 months, grants and personal fees from Amgen and Eli-Lilly and Company, grant from Celgene, and personal fees from Alder Biopharmaceuticals, Aeon Biopharma, Allergan, Biohaven Pharmaceuticals Inc., Clexio, Electrocore LLC, eNeura, Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, MundiPharma, Novartis, Pfizer, Sanofi, Santara Therapeutics, Teva Pharmaceuticals, Trigemina Inc., WL Gore, and personal fees from MedicoLegal work, Massachusetts Medical Society, Up-to-Date, Oxford University Press, and Wolters Kluwer; and a patent magnetic stimulation for headache assigned to eNeura without fee.
: This study using human participants was approved by the Camden and King’s Cross Research Ethics Committee in February 2015 (14/LO/2241). The study was also approved by King’s College Hospital Research and Development Committee.
: All subjects enrolled in the study gave informed written consent for participation, according to the Declaration of Helsinki.